This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Salud financiera de hoja de balance de RegenETP

Salud financiera controles de criterios 4/6

RegenETP tiene un patrimonio de los accionistas total de $12.4M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $18.0M y $5.6M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$6.39m
Patrimonio	US$12.42m
Total pasivo	US$5.63m
Activos totales	US$18.05m

Actualizaciones recientes sobre salud financiera

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($8.9M) de NJT superan a sus pasivos a corto plazo ($2.2M).

Pasivo a largo plazo: Los activos a corto plazo de NJT ($8.9M) superan a sus pasivos a largo plazo ($3.5M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: NJT está libre de deudas.

Reducción de la deuda: NJT no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: NJT tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: NJT tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 0.5% cada año

This company listing is no longer active

Salud financiera de hoja de balance de RegenETP

Salud financiera controles de criterios 4/6

Información clave

Actualizaciones recientes sobre salud financiera

PolarityTE, Inc. announced delayed 10-Q filing

PolarityTE, Inc. Files Form 15

Nasdaq to Delist the Common Stock of PolarityTE

PolarityTE's Common Stock To Be Delisted From Nasdaq

PolarityTE, Inc. Receives Deficiency Letter the Listing Qualifications Department of Nasdaq

PolarityTE Receives A Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Recent updates

RegenETP, Inc. announced that it expects to receive $22.5 million in funding from Avenue Capital Group, LLC

PolarityTE Screens First Subject in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers

PolarityTE, Inc. Announces Resignation of Jacob Patterson as Chief Financial Officer

PolarityTE, Inc. announced delayed 10-Q filing

PolarityTE, Inc. Files Form 15

Nasdaq to Delist the Common Stock of PolarityTE

PolarityTE, Inc.(OTCPK:PTEI.Q) dropped from NASDAQ Composite Index

PolarityTE's Common Stock To Be Delisted From Nasdaq

First quarter 2023 earnings released: US$0.58 loss per share (vs US$1.12 loss in 1Q 2022)

Forecast to breakeven in 2025

Polarityte, Inc. Appoints Jeff Dyer as A Member of the Board of Directors

Insufficient new directors

Forecast to breakeven in 2025

Third quarter 2022 earnings released: US$0.47 loss per share (vs US$0.31 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.47 loss per share (vs US$0.31 loss in 3Q 2021)

Michael Brauser submitted a non-binding offer to acquire the remaining stake in PolarityTE, Inc. (NasdaqCM:PTE).

PolarityTE, Inc. Receives Deficiency Letter the Listing Qualifications Department of Nasdaq

PolarityTE, Inc. Announces Resignation of Jeff Dyer from its Board of Directors

Second quarter 2022 earnings released: US$0.013 loss per share (vs US$0.99 loss in 2Q 2021)

PolarityTE, Inc. to Report Q2, 2022 Results on Aug 11, 2022

First quarter 2022 earnings released: US$0.045 loss per share (vs US$0.23 loss in 1Q 2021)

PolarityTE, Inc. Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to SkinTE(R)

PolarityTE, Inc. to Report Q1, 2022 Results on May 16, 2022

Full year 2021 earnings released: US$0.38 loss per share (vs US$1.11 loss in FY 2020)

PolarityTE, Inc. Announces Results from Multi-Center Randomized Controlled Trial Evaluating Treatment of Venous Leg Ulcers with Its Investigational Product SkinTE plus standard of care vs SOC alone

PolarityTE, Inc. Announces Allowance of Fourth U.S. Patent

PolarityTE, Inc Announces U.S. FDA Approval of IND for Pivotal Phase 3 Study of SkinTE® to Support Chronic Cutaneous Ulcer Indication

PolarityTE, Inc. Announces Submission of Complete Response to Fda's Clinical Hold Correspondence for Skinte® Investigational New Drug Application

Third quarter 2021 earnings released: US$0.013 loss per share (vs US$0.18 loss in 3Q 2020)

Gainey Mckenna & Egleston Announces A Class Action Lawsuit Filed Against PolarityTE, Inc

Independent Director Minnie Baylor-Henry has left the company

PolarityTE Provides Update on U.S. FDA Investigational New Drug Application for SkinTE®

PolarityTE Receives A Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Second quarter 2021 earnings released: US$0.04 loss per share (vs US$0.33 loss in 2Q 2020)

Independent Chairman of the Board recently bought €212k worth of stock

First quarter 2021 earnings released: US$0.23 loss per share (vs US$0.40 loss in 1Q 2020)

PolarityTE, Inc. Updates on SkinTE Biologic License Application

PolarityTE Announces Diabetic Foot Ulcer Trial Met Primary and Secondary Endpoint

PolarityTE, Inc. to Report Fiscal Year 2020 Results on Mar 30, 2021

PolarityTE, Inc. Announces Submission of an Investigational New Drug Application

New 90-day high: €1.23

PolarityTE Announces Completion of Target Enrollment in Diabetic Foot Ulcer Trial

PolarityTE, Inc. has completed a Follow-on Equity Offering in the amount of $10.000001 million.

New 90-day high: €0.98

New 90-day low: €0.53

Polarityte Announces Dismissal of Securities Class Action Complaint with Prejudice

New 90-day low: €0.57

Third quarter 2020 earnings released: US$0.18 loss per share

Revenue beats expectations

PolarityTE Announces Successful Completion of Initial Pre-IND Interaction with U.S. Food and Drug Administration for SkinTE®

PolarityTE, Inc. to Report Q3, 2020 Results on Nov 09, 2020

New 90-day low: €0.82

PolarityTE Receives NIH Grant for a Point-of-Care Device to Treat Chronic Wounds

New 90-day low: €0.85

PolarityTE, Inc. Announces SkinTE™ Health Economics — DFU Interim Analysis Data Demonstrates Potential for Cost Savings and Improved Wound Closure

New 90-day low - €0.94

First half earnings released

New 90-day high - €1.47

PolarityTE, Inc.(NasdaqCM:PTE) dropped from Russell Small Cap Completeness Index

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera